Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456159 | 0.79 | SLC6A1 (0.30) | SLC6A11SLC6A1TYMP | |
| SCHEMBL23455982 | 0.79 | HTR1A (0.33) | SLC6A11SLC6A1TYMP | |
| SCHEMBL23455994 | 0.79 | SLC6A1 (0.30) | SLC6A11SLC6A1 | |
| SCHEMBL23455986 | 0.73 | BCHE (0.37) | KMT2A | |
| SCHEMBL6414906 | 0.73 | SLC6A11 (0.51) | SLC6A11SLC6A1KIF11MEN1TP53 | |
| SCHEMBL6409688 | 0.73 | SLC6A11 (0.51) | SLC6A11SLC6A1KIF11MEN1TP53 | |
| SCHEMBL18349616 | 0.72 | SLC6A11 (0.45) | SLC6A11SLC6A1TYMPKIF11MEN1 | |
| SCHEMBL6406106 | 0.71 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11MEN1TP53 | |
| SCHEMBL6407715 | 0.71 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11MEN1TP53 | |
| SCHEMBL22879134 | 0.70 | MEN1 (0.43) | SLC6A11SLC6A1TYMPKIF11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3707151-B1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICALS CO (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | SLC6A11 3399/4885SLC6A1 3437/4885TYMP 1316/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | SLC6A11 3399/4885SLC6A1 3437/4885TYMP 1316/4885 |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | SLC6A11 3399/4885SLC6A1 3437/4885TYMP 1316/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | SLC6A11 3399/4885SLC6A1 3437/4885TYMP 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.